Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?

LAUR Repository

Show simple item record

dc.contributor.author Brouquet, Antoine
dc.contributor.author Overman, Micheal
dc.contributor.author Kopetz, Scott
dc.contributor.author Maru, Dipen
dc.contributor.author Loyer, Evelyne
dc.contributor.author Andreou, Andreas
dc.contributor.author Cooper, Amanda
dc.contributor.author Curley, Steven
dc.contributor.author Garrett, Christopher
dc.contributor.author Abdalla, Eddie
dc.contributor.author Vauthey, Jean-Nicolas
dc.date.accessioned 2015-11-19T09:54:29Z
dc.date.available 2015-11-19T09:54:29Z
dc.date.copyright 2011
dc.date.issued 2017-05-23
dc.identifier.issn 0008-543X en_US
dc.identifier.uri http://hdl.handle.net/10725/2628
dc.description.abstract BACKGROUND: Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown. METHODS: From August 1998 to June 2009, data from 1099 patients with CLM were collected prospectively. We retrospectively analyzed outcomes of patients who underwent resection of CLM after second-line (2 or more) chemotherapy regimens. RESULTS: Sixty patients underwent resection of CLM after 2 or more chemotherapy regimens. Patients had advanced CLM (mean number of CLM ± standard deviation, 4 ± 3.5; mean maximum size of CLM, 5 ± 3.2 cm) and had received 17 ± 8 cycles of preoperative chemotherapy. In 54 (90%) patients, the switch from the first regimen to another regimen was motivated by tumor progression or suboptimal radiographic response. All patients received irinotecan or oxaliplatin, and the majority (42/60 [70%]) received a monoclonal antibody (bevacizumab or cetuximab) as part of the last preoperative regimen. Postoperative morbidity and mortality rates were 33% and 3%, respectively. At a median follow-up of 32 months, 1-year, 3-year, and 5-year overall survival rates were 83%, 41%, and 22%, respectively. Median chemotherapy-free survival after resection or completion of additional chemotherapy administered after resection was 9 months (95% confidence interval, 4-14 months). Synchronous (vs metachronous) CLM and minor (vs major) pathologic response were independently associated with worse survival. CONCLUSIONS: Resection of CLM after a second-line chemotherapy regimen was found to be safe and was associated with a modest hope for definitive cure. This approach represents a viable option in patients with advanced CLM. Cancer 2011;. © 2011 American Cancer Society. en_US
dc.language.iso en en_US
dc.title Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Cancer en_US
dc.journal.volume 117 en_US
dc.journal.issue 19 en_US
dc.article.pages 4484-4492 en_US
dc.keywords Colorectal liver metastases en_US
dc.keywords Liver resection en_US
dc.keywords Second-line chemotherapy en_US
dc.keywords Outcome en_US
dc.identifier.doi http://dx.doi.org/10.1002/cncr.26036 en_US
dc.identifier.ctation Brouquet, A., Overman, M. J., Kopetz, S., Maru, D. M., Loyer, E. M., Andreou, A., ... & Vauthey, J. N. (2011). Is resection of colorectal liver metastases after a second‐line chemotherapy regimen justified?. Cancer, 117(19), 4484-4492. en_US
dc.author.email eddie.abdalla@lau.edu.lb
dc.identifier.url http://onlinelibrary.wiley.com/doi/10.1002/cncr.26036/full

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account